Omada Health recorded Q4 revenue of $75.85 million, a 58% increase year-over-year, and reported earnings of $0.08 per share compared to a $0.03 loss estimate. The results reflect strong adoption of its digital chronic care services and exceeded expectations on both top and bottom lines.

The GLP-1 Flex Care offering enables employers to manage medication costs while providing clinical oversight and guidance. The program now supports over 150,000 members on GLP-1 therapy—up from 50,000 at the end of 2024—with a 67% one-year persistence rate among participants.

Omada forecasts fiscal-2026 sales between $312 million and $322 million, compared with a $311.41 million consensus estimate. Management cited expanding employer adoption and program enhancements as drivers for targeting over $300 million in annual revenue.

Shares climbed more than 10% in premarket trading, trading 31.6% above the 20-day moving average but 9.1% below the 100-day average. Neutral RSI readings alongside a bullish MACD suggest potential upside, while analysts maintain mostly Buy ratings with an average price target near $24.18.